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Background: Autogenous vein grafts are commonly used for arterial reconstructive procedures. Their success is limited by
the development of intimal hyperplasia (IH), a fibroproliferative disease that predisposes the grafts to occlusive stenosis.
Mesenchymal cell proliferation and the deposition of an extracellular matrix characterize neointimal development.
Increasing evidence suggests that, regardless of blood vessel type, IH results from complex interactions among vessel wall
cells, infiltrating leukocytes, and cytokines. Transforming growth factor-1 (TGF-1) is a pleiotropic cytokine with
powerful effects on inflammatory cell chemotaxis; smooth muscle cell, fibroblast, and endothelial cell proliferation; and
extracellular matrix synthesis.
Methods: Epigastric vein to common femoral artery interposition grafts were placed in male Lewis rats and harvested at 1,
2, 4, and 12 weeks after surgery. We used replication-defective adenoviruses to deliver a control reporter gene for the
enzyme -galactosidase (Ad-GAL), empty virus (Ad-CMVpLpA), or the sequence encoding the antisense strand of
TGF-1 (Ad-AST). The vein graft was transduced passively inmedium containing 107 plaque-forming units per milliliter
of Ad-GAL, Ad-CMVpLpA, or Ad-AST for 20 minutes at room temperature. The adenovirus-treated grafts were
compared with grafts treated with medium without virus (sham).
Results: The Ad-GAL control grafts showed -galactosidase activity from 3 days to 4 weeks. Twenty percent of cells were
positive out to 2 weeks, at which time the number of cells positive for -galactosidase activity began to decline. Treatment
with Ad-AST resulted in a significant reduction vs sham, Ad-CMVpLpA, and Ad-GAL in TGF-1 messenger RNA, total
TGF-1 protein, and bioactive TGF-1 protein. Neointimal area was significantly reduced in the Ad-AST group vs
Ad-GAL at 4 weeks, vs Ad-CMVpLpA at 4 and 12 weeks, and vs sham at 2 and 4 weeks. The medial/adventitial layer was
significantly thicker in the Ad-AST group than the Ad-GAL group at 12 weeks. In addition, we studied the effect of
Ad-AST on monocyte chemotactic protein 1 (MCP-1). Although the reduction in TGF-1 resulted in a reduction of
MCP-1messenger RNA in whole-graft homogenates andMCP-1 protein–positive staining in histologic sections from the
perianastomotic region, no reduction in the number of ED1-positive cells (monocytes and macrophages) was observed.
Conclusions: Perioperative antisense TGF-1 treatment of the vein to be used in arterial reconstructions resulted in a
prolonged diminution of IH; this emphasizes the importance of TGF-1 in neointimal thickening and indicates that ex
vivo gene therapy can reduce the vessel’s predisposition to IH. (J Vasc Surg 2005;41:498-508.)
Clinical Relevance:Themain cause of occlusion and graft failure after peripheral and cardiac arterial reconstruction is IH.
The study of the mechanisms and mediators of IH, including TGF-1, should lead to future gene therapies to prevent or
limit IH. The clinical effect of such treatments would be enormous, because they would increase graft longevity, thereby
enhancing quality of life and enabling patients to live without the threat of limb loss or recurrent heart attack.The main cause of occlusion and graft failure after
peripheral and cardiac arterial reconstruction is intimal
hyperplasia (IH). The study of the mechanisms and medi-
ators of IH, including transforming growth factor (TGF-
1), should lead to future gene therapies to prevent or limit
IH. The clinical effect of such treatments would be enor-
mous, because they would increase graft longevity, thereby
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498enhancing quality of life and enabling patients to live
without the threat of limb loss or recurrent heart attack.
Autologous vein grafts remain the preferred conduit for
many arterial reconstructive procedures. Unfortunately,
the long-term success of such grafts is compromised by IH,
a fibroproliferative growth of a neointima into the vessel
lumen that often leads to stenosis and graft failure. Al-
though the understanding of IH development is limited,
one theory suggests that it begins as a wound-healing
response to vessel trauma and evolves into a chronic con-
dition of unchecked cellular proliferation and extracellular
matrix (ECM) production.1,2 Cytokines help to maintain
homeostasis in normal vascular tissues by regulating cell
development and differentiation and enabling cell commu-
nication. Dysregulation of cytokine pathways is likely to
result in abnormal wound healing and vascular disorders
such as IH.
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on inflammatory cell chemotaxis; smooth muscle cell
(SMC), fibroblast, and endothelial cell (EC) proliferation;
and ECM synthesis. Experiments with knockout and trans-
genic mice have confirmed its essential nature.3-6 This
factor is known to have powerful effects on cell growth,
development, interactions, and death and can behave in
both an autocrine and a paracrine fashion.7 It is thought to
have a pivotal role in cardiovascular development and
pathobiology,8,9 although knowledge of its function in
vein graft IH is limited. The biology of TGF-1, one of five
isoforms, has been described in numerous comprehensive
reviews.10-12 Cellular sources of TGF-1 include plate-
lets,13 ECs,14 SMCs,15 myofibroblasts,16 macrophages,17
neutrophils,18 and T lymphocytes.19 All of these cells par-
ticipate in the remodeling of the healing vein graft20 and
may be contributing bioactive TGF-1 during IH develop-
ment. Increased expression of TGF-1 has been demon-
strated in human atherosclerotic plaque, re-stenotic arter-
ies, and vein grafts.21-23 Upregulation of TGF-1 is also
found during IH development in rat arteries after stent-
ing.24
We hypothesized that reducing TGF-1 in healing vein
grafts would alter the progression of vein graft disease. In
these studies, we used gene therapy, via an adenovirally
delivered antisense sequence to tgf-1, to show a pro-
longed diminution of IH with antisense tgf-1 treatment.
We quantified the effect of altering tgf-1 messenger RNA
(mRNA) on TGF-1 protein expression, the morphomet-
ric parameters of IH (neointimal area and cellularity),
mRNA and protein expression of monocyte chemotactic
protein 1 (MCP-1), and monocyte and macrophage infil-
tration of vein grafts.
METHODS
Adenoviral transduction, microsurgery, and harvest.
Rat epigastric vein-to-femoral artery interposition grafts
were placed and harvested as previously described.25 Ani-
mal care complied with the Principles of Laboratory Ani-
mals (formulated by the National Society for Medical Re-
search) and the Guide for the Care and Use of Laboratory
Animals (National Academy Press). Procedures were ap-
proved by the Research Animal Resources Center at the
University of Wisconsin-Madison. For adenoviral trans-
duction, 8 mm of freshly harvested, cannulated, and irri-
gated epigastric vein was allowed to passively dwell ex vivo
in an adenoviral solution (107 plaque-forming units
[PFU]/mL). The four treatments were infection with ad-
enovirus expressing mRNA antisense to tgf-126 (Ad-
AST); infection with adenovirus expressing the gene for
-galactosidase (Ad-GAL); infection with adenovirus with-
out any expressing gene (Ad-CMVpLpA); and a soak in
solution without virus (sham). The Ad-AST construct ex-
presses the antisense mRNA to the full-length TGF-1
protein (coding region plus 130 base pairs of 5= untrans-
lated region; 1303 base pairs), which includes the latency-
associated protein (pro region). Both the Ad-GAL and
Ad-AST constructs use the cytomegalovirus promoter. In-fection was allowed to proceed for 20 minutes at room
temperature. Subsequently, the transfected vein was rinsed
with phosphate-buffered saline and implanted in place of a
3-mm resection of femoral artery. Grafts were harvested at
four time points (1, 2, 4, and 12 weeks after grafting). The
patency rate of harvested grafts was 95% or more. When a
graft was found not to be patent, it was not used in the
analysis, and another graft was implanted to take its place.
Contralateral epigastric veins, spleens, and sera were har-
vested as positive or negative control tissues for immuno-
histochemistry (IHC), enzyme-linked immunosorbent as-
say (ELISA), and/or quantitative polymerase chain
reaction (qPCR). Tissue was processed according to previ-
ously published methods, with modifications.25 Briefly,
grafts to be used for mRNA and protein analysis were
excised, placed in liquid nitrogen, and then stored at
70°C (n 5 for each treatment/time point). Grafts to be
used for histology and IHC were placed in 4% paraformal-
dehyde overnight at 4°C before being embedded in paraffin
(n  5 for each treatment/time point).
RNA extraction, reverse transcription, and qPCR.
After the graft was homogenized for approximately 15
seconds in 0.2 mL of ice-cold buffer containing protease
and ribonuclease (RNase) inhibitors, a 0.05-mL aliquot of
the homogenate was immediately transferred to 0.4 mL of
Trizol (Invitrogen, (Carlsbad, Calif)) and vortexed to de-
nature any RNases. (The remaining 0.15 mL of each ho-
mogenate was used in ELISAs.) Glycogen was used as a
carrier to increase the yield of mRNA. Chloroform extrac-
tions, washes, and precipitations were performed. Purity
and yields were determined by spectrophotometry. North-
ern analysis has shown this method to yield high-quality
RNA.
Deoxyribonuclease-treated (DNA Free; Ambion, Aus-
tin, Tex) RNA (5 g) was reverse-transcribed with Super-
script II (Invitrogen) according to the manufacturer’s in-
structions. The resulting complementary DNA was RNase-
treated (RNase H; Invitrogen) and stored at 20°C until
use. Yields of complementary DNA were quantified by
fluorescence spectrometry, and samples were diluted to 20
ng/L.
For qPCR, we pipetted three standard curves (mcp-1,
tgf-1, and the housekeeping gene hypoxanthine phospho-
ribosyltransferase [hprt]). In the same run as the standard
curves, four reactions of each sample (1, 1, 2, and 2 L of
sample) were run for each primer set (mcp-1, tgf-1, and
hprt) on a Rotor-Gene 2000 (Corbett Research, Sydney,
Australia). Cycle threshold vs the appropriate standard
curve was used to determine copies of mcp-1 or tgf-1 per
copy of hprt. Comparing the results from reactions using 1
L of sample with the results of reactions that used 2 L of
sample confirmed that the measurements were quantita-
tive. The four estimates of mcp-1 or tgf-1 copies per copy
of hprt were then averaged to give the result for each
sample. Primers were designed to include a splice site in the
amplicons as a control for the presence of genomic DNA.
In addition, for tgf-1, the 5= primer was located in the
region of overlap with the antisense treatment, and the 3=
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antisense treatment. This primer design avoided amplifica-
tion of the virally delivered antisense mRNA.
Enzyme-linked immunosorbent assays. To each
0.15 mL of homogenate, 1.5 L of Triton X-100 (Sigma,
St Louis, Mo) was added. After mixing, the solution was
incubated on ice for 30 minutes with vortexing every 10
minutes. Particulates were pelleted by centrifugation
(15,000g for 15 minutes at 4°C). ELISA experiments for
TGF-1 were performed on supernatants according to the
manufacturer’s (Promega, Madison, Wis) instructions us-
ing 96-well half-area plates. Latent TGF-1 was converted
to bioactive TGF-1 by an acid activation followed by
neutralization so that total and bioactive TGF-1 protein
in the sample could be assayed. ELISA experiments for
MCP-1 used a Research Diagnostics Inc (Flanders, New
Jersey) monoclonal antibody (RDI-RTMCP1) as the cap-
ture antibody and Peprotech rabbit anti–MCP-1 (500-
P76) as the detection antibody. Color was developed by
using goat anti-rabbit horseradish peroxidase (Sigma) and
3,3’-tetramethylbenzidine from Vector Labs (Burlingame,
Calif).
Histochemistry and IHC. Histochemistry and IHC
were performed according to previously published meth-
ods, with modifications.20,25,27-29 Tissue from the proxi-
mal graft region (3 mm from the anastomosis) was cut
transversely into sections. To eliminate sampling bias due
to IH eccentricity, three 5-m sections, 800 m apart,
were measured and averaged. For each time point, a mean
of all grafts was derived. Hematoxylin and eosin–stained
sections were used for measurement of areas and cell num-
bers. IHC used antibodies to TGF-1 (MA246; R&D
Systems, Minneapolis, Minn), monocytes and macro-
phages (ED1; Serotec, Raleigh, NC), and MCP-1 (Pepro-
tech, Rocky Hill, NJ). The area of positive staining was
measured by using digitized image analysis and a fixed
threshold for stain intensity. To ensure specificity of the
IHC, parallel staining with negative-control primary anti-
bodies was performed. Primary antibody specificity was
tested by using various positive and negative control tis-
sues. Detection of the primary antibody and color develop-
ment was performed with the Universal DAKO LSAB 2
Kit, Peroxidase, for use on RAT Specimens (DAKO,
Glostrup, Denmark) and the DAKO Liquid DAB Large
Volume Substrate-Chromogen System, according to the
manufacturer’s instructions.
Videomorphometry. Images of vein graft cross sec-
tions were captured by using a Nikon microscope (Tokyo,
Japan) and a Pixera color camera (Pixera Corporation, Los
Gatos, Calif). Various morphometric parameters, such as
the total cross-sectional area, neointimal area, and area of
positive immunostaining, were measured by using image
analysis (MetaMorph software; Universal Imaging, Down-
ingtown, Pa).27 A range of red, green, and blue intensities
were defined to identify stained cells but exclude unstained
cells. Once this range was determined, it was saved and used
by the MetaMorph software to identify stained cells on all
sections with no further input by the operator. Verhoff’selastic fiber stain was used to define the boundary between
the neointima and the media.
Statistical methods. The statistical experimental de-
sign used a completely randomized design. The random-
ized design used to assign animals to treatments and time
points was carried over into the IHC analysis so that if there
were day-to-day (or slide-to-slide) variations in staining,
the biases would average out to be zero. This ensured that
biases between experimental groups were, on average, zero.
Because of this, we can be confident that any statistically
significant differences we detected between treatment
groups or over time within a group were caused by the
experimental treatments.
All analyses were performed with SAS statistical soft-
ware (SAS Institute Inc, Cary, NC). P values .05 were
considered significant. Values are expressed as mean 
SEM. By performing qPCR and ELISA on the same ho-
mogenate from individual grafts, we can measure multiple
factors within each vein by both reverse transcriptase-poly-
merase chain reaction and ELISA. This enables us to assess
within-vein associations and test for between-treatment
effects simultaneously by using multivariate analysis of vari-
ance. To compare the production of mRNA of two differ-
ent genes, tgf-1 and MCP-1, across the three treatments
and four time points, we used a split-plot analysis of vari-
ance model. After log-transforming (less extreme values
and more equivalent group variances) the mRNA values to
better meet the assumptions of the analysis of variance, SAS
PROC MIXED, with a random rat effect, was used to test
the main effects and all possible interactions. We tested for
treatment effects across genes by using Fisher protected
least significant difference tests of the treatment  gene
interaction least squares means. An analysis of covariance of
log-transformedmRNA values was used to test our hypoth-
esis that the mcp-1 levels were responding to the level of
TGF-1, and not necessarily to the treatment.
RESULTS
Adenoviral gene transfer. To optimize the transfec-
tion frequency, we infected freshly harvested epigastric
veins before grafting with Ad-GAL at 0 (diluent alone),
107, 108, and 109 PFU/mL, with five rats per dose. Grafts
were harvested at 3 days, and tissue was assessed for -
galactosidase expression. For diluent alone, background
staining was 2.2%  1.08% of vein wall cells. The percent-
age of vein wall cells expressing -galactosidase was 27%
5%, 26%  3%, and 27%  7% for treatment with virus at
107, 108, and 109 PFU/mL, respectively. Because a high
multiplicity of infection is known to be toxic, 107 PFU/mL
was deemed as the optimal dose. Cells expressing -galac-
tosidase were seen through 4 weeks (Fig 1), thus indicating
sustained gene expression with this system. Examination by
light microscopy indicated that myofibroblasts30 were in-
cluded in the cell types expressing -galactosidase.
Two concentrations of adenovirus Ad-AST construct
(107 and 108 PFU/mL) were tested. No difference in
inhibition of neointimal hyperplasia was seen between the
two treatments at 2 or at 4 weeks (data not shown).
-gal
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experiments. Primers specific for Ad-AST (antisense tgf-1
with an SV40 3= untranslated region) were used to estimate
the duration of Ad-AST expression. Antisense tgf-1 could
be detected by polymerase chain reaction in 100% of
1-week, 75% of 2-week, 25% of 4-week, and 25% of 12-
week grafts. Antisense TGF-1 was not detected in vein
grafts that were not treated with Ad-AST.
TGF-1 mRNA and protein are reduced in grafts
treated with antisense tgf-1. Using primers specific for
the native tgf-1 mRNA, Ad-AST treatment greatly re-
ducedmRNA coding for TGF-1 throughout the 12-week
study (Fig 2). The total and, more importantly, bioactive
TGF-1 protein was also reduced by the antisense treat-
ment (Fig 3).
In the sham control group, the tgf-1 message peaked
at 2 weeks, whereas total and bioactive TGF-1 protein
peaked at 4 weeks. This time course is consistent with our
earlier results in this vein graft model. In the Ad-GAL
group, the tgf-1message was at similar levels to sham and
Ad-CMVpLpA at 2 and 4 weeks, but tgf-1 message was
increased compared with sham or Ad-CMVpLpA at 1 week
and 12 weeks. In addition, a trend was observed in which
bioactive protein was increased in the Ad-GAL treatments
vs the sham or Ad-CMVpLpA treatments (Figs 2 and 3).
To complement the TGF-1 qPCR and ELISA data
Fig 1. Adenovirus gene expression is seen out to 4 wee
units per milliliter of adenovirus containing the gene
harvested at the indicated time points and soaked in a
microscopically. For each time point, n  5 vein grafts.from whole grafts, IHC was performed on paraffin-embed-ded vein grafts from rats with Ad-AST, Ad-GAL, sham, and
Ad-CMVpLpA treatments. These sections were taken from
the perianastomotic region. This perianastomotic region
historically shows the most IH. These IHC results showed
a reduction in TGF-1–positive staining in Ad-AST vs
sham at 2, 4, and 12 weeks and vs Ad-GAL at 4 and 12
weeks (Fig 4). The reduction in TGF-1–positive staining
in Ad-AST vs Ad-CMVpLpA did not reach significance
(Fig 4). The sections from the Ad-AST–treated grafts did
have a TGF-1 staining pattern different from that of the
sections from grafts treated with Ad-CMVpLpA, sham, or
Ad-GAL. Sections from Ad-AST grafts showed light stain-
ing of the adventitia. Sections from the control treatments
showed staining for TGF-1 throughout the vessel wall.
Adenoviral antisense tgf-1 treatment reduces IH.
Histologically, the Ad-AST grafts showed attenuation of
IH compared with controls (Fig 5). Histologic measure-
ments were made on hematoxylin and eosin–stained sec-
tions of vein grafts. Neointimal and adventitial/medial area
measurements were made and are presented in Table I. The
adventitial and medial layers merge during the maturation
of the vein graft so that they are combined in these area
measurements. IH is significantly reduced by Ad-AST at 4
and 12 weeks when compared with Ad-CMVpLpA and at 4
weeks when compared with Ad-GAL. Compared with
sham, the reduction in IH is significant at 2 and 4 weeks.
rafts were treated ex vivo with 1  107 plaque forming
-galactosidase before placement. The grafts were then
ion containing -Gal before being fixed and examined
, -Galactosidase.ks. G
for 
solutAd-AST was also shown to preserve the medial/adventitial
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in the Ad-AST group and was significantly thicker than that
found in the Ad-GAL group (Table I). Ad-AST also re-
sulted in a significant increase in cellularity (number of cells
per total cross-sectional area) at all time points vs sham and
at 1, 2, and 12 weeks vs Ad-GAL and Ad-CMVpLpA. Table
I shows the number of cells found in each layer of the vein
graft.
Assessment of MCP-1 mRNA and protein
expression. mcp-1 mRNA levels were lowest in the Ad-
AST group (P  .05 vs each control group), and the
relationship between treatment andmcp-1mRNA response
did not significantly change with time (Fig 6). Because
mcp-1 (a chemoattractant for monocytes/macrophages)
and tgf-1 mRNA levels were measured in the same sam-
ples, we were able to analyze the relationship between these
cytokines by an analysis of covariance. The results of the
statistical analysis indicated that the observed reduction in
mcp-1 mRNA was due to the reduction in tgf-1 (P 
.0001). If the effect of changing the expression of tgf-1 is
accounted for, then the Ad-AST treatment itself had no
significant effect (P  .74) on the mcp-1 mRNA level.
MCP-1 protein was analyzed both by using enzyme-
Fig 2. Expression of antisense to transforming growth f
RNA (mRNA). The grafts were harvested at the indica
homogenized; the mRNA was extracted and reverse-
polymerase chain reaction, with normalization to mRNA
illustrative purposes, ‡P  .01; however, statistical anal
change with time.When time is removed as a factor, the re
vs Ad-GAL, sham, or Ad-CMVpLpA). Results from
treatment/time point, n  5 vein grafts.linked immunostaining of paraffin sections and by ELISAof supernatants from whole-graft homogenates. In the
paraffin sections, which come from the perianastomotic
region of the grafts, a significant reduction in area of the
cross section staining positive for MCP-1 was observed at 4
weeks (P  .05 vs each control group). When whole-graft
homogenates were analyzed by ELISA for MCP-1, no
significant differences were observed among the Ad-AST,
Ad-GAL, Ad-CMVpLpA, and shamgroups at any time point.
Assessment of macrophage/monocytes. Because we
observed a general reduction inmcp-1mRNA and a reduc-
tion in perianastomotic MCP-1 protein at 4 weeks by
Ad-AST treatment, we performed immunostaining for
monocytes/macrophages in the perianastomotic region of
the vein grafts. Although a general trend could be seen
wherein infiltrating macrophages could be seen at 1 week,
peak infiltration was at 2 to 4 weeks, and remaining mac-
rophages were aligned with the internal elastic lamina at 12
weeks; no change in ED1-positive cells (monocytes and
macrophages) was seen with Ad-AST treatment.
DISCUSSION
To interfere with tgf-1 gene expression and, thus, to
study its effects during IH development, we transduced rat
1 (tgf-1) greatly reduces the level of tgf-1messenger
ime points, rinsed with phosphate-buffered saline, and
ribed; and measurements were made by quantitative
s of hypoxanthine phosphoribosyltransferase (hprt). For
dicated that the relationships between groups did not
ion of tgf-1mRNAby Ad-AST is significant (P .0001
rafted epigastric vein are given as time 0. For eachactor
ted t
transc
level
ysis in
duct
ungvein grafts ex vivo before implantation with adenovirus-
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The grafts were harvested at the indicated time points, rinsed with phosphate-buffered saline, and homogenized, and
the supernatants were analyzed by enzyme-linked immunosorbent assay (ELISA). Top, Acid activation followed by
neutralization allowed measurement of the total TGF-1 in the sample. Bottom,Without acid activation, the ELISA
was specific for bioactive TGF-1. The reduction in total and bioactive TGF-1 was significant vs each control at each
time point (‡P  .01; *P  .05). Results from ungrafted epigastric vein are given as time 0. For each treatment/time
point, n  5 vein grafts.
, n 
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vein grafts with Ad-AST resulted in decreased expression of
TGF-1mRNA and protein, reduction of IH, preservation
of the medial/adventitial layer, and reduction in mcp-1
mRNA.
TGF-1 is known to stimulate smooth muscle 	-actin
expression in fibroblasts from a variety of tissues,31 and
TGF-1 is a potent stimulator of vascular myofibroblast
ECM synthesis,32 thus suggesting an important role for this
cytokine in the phenotypic modulation of vascular cells and
in the development of arterial IH.16 After porcine arterial
injury, TGF-1 was initially expressed in adventitial fibro-
blasts, which later expressed both TGF-1 and 	-actin,
thus implying a myofibroblast phenotype.16 In wounds,
myofibroblasts are responsible for contractile phenomena
and for the deposition of excessive amounts of ECM.33-35
TGF-1 has been shown to influence the differentiation of
myofibroblasts during wound healing.36 TGF-1 may act
on cells directly or by modulating the gene expression of
other proteins. In arterial injury, myofibroblasts migrate
and proliferate to form a neointima. We have shown that
myofibroblasts are also the predominant cell type repopu-
lating the wall of the healing rat vein graft.20 Majesky et al15
correlated increased tgf-1 mRNA levels with increases in
mRNA expression of fibronectin and the collagens 	2 (I)
and 	1 (III) during IH development after arterial balloon
Fig 4. Vein graft cross sections show reduced transform
harvested at the indicated time points, fixed, and paraffin
by using a monoclonal antibody specific to TGF-1. Ov
Ad-AST grafts showed the least. ‡P .01; *P .05 vs Ad
vein are given as time 0. For each treatment/time pointinjury. When soluble TGF-R:Fc is used to block theaction of TGF-1, fibroblast transdifferentiation is inhib-
ited, and mRNA of fibrillar collagens and adventitial colla-
gen deposition is decreased, without a reduction in adven-
titial cell proliferation.32,37
The goal of our adenovirus delivery of antisense to
tgf-1 was to reduce the amount of IH in vein grafts by
reducing the production of ECM. Even though antisense
to full-length transcript reliably knocks down the target
gene, off-target effects are commonly observed. We have
not performed gene arrays to see whether the histologic
results observed could have been from knock-downs of
related genes such as tgf-2, tgf-3, and so on or knock-
downs of some nonrelated gene(s). However, the results
observed do coincide with the known actions of TGF-1.
Because TGF-1 is a bifunctional modulator of cell death
that exerts a proapoptotic influence on ECs38 and is anti-
apoptotic for vascular SMCs,39 our Ad-AST treatment is
likely preserving ECs and reducing the accumulation of
synthetic cells, ie, cells that produce collagen and other
proteins of the ECM. An alternative explanation for the
increased cellularity with Ad-AST would be an increase in
infiltrating cells caused by the presence of adenovirus.
However, no significant difference in the presence of
monocytes/macrophages was found with adenovirus treat-
ment. The increase in cellularity with a decrease in neoin-
rowth factor 1 (TGF-1) expression. The grafts were
dded. Sections were subjected to immunohistochemistry
sham grafts showed the most staining for TGF-1, and
at the same time point. Results from ungrafted epigastric
5 vein grafts.ing g
embe
erall,
-ASTtimal area implies that reduced ECM synthesis is primarily
. (The
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ment.
MCP-1 is a member of the C-C chemokine family and
is a potent chemotactic factor for lymphocytes.40 This
Fig 5. Micrographs of 12-week vein grafts show reduc
before implantation with adenovirus that expressed -ga
1 (top right), or empty virus (bottom left). Ungrafted ep
is dramatically diminished in the antisense-treated graf
indicate the internal elastic laminas. L, Lumen; N, neoin
magnification.
Table I. Area and cell numbers of vein graft wall layers
Treatment Time zero 1 wk
Neointimal area (m2)
Control vein 9982 (109)
Ad-AST 37,398 (63
Ad-GAL 39,814 (33
Ad-CMVpLpA 28,497 (13
Sham 35,910 (28
Adventitial and medial area
Control vein 138,489 (691)
Ad-AST 178,652 (30
Ad-GAL 163,492 (99
Ad-CMVpLpA 197,255 (16
Sham 152,359 (21
*P .05 between Ad-AST area and one or more of the control group’s areafactor is thought to have a pivotal role in the accumulationof macrophage-rich lesions in atherosclerosis and re-steno-
sis.41,42 We have demonstrated increased MCP-1 mRNA
and protein up to 12 weeks after vein grafting.27 Both
graft-infiltrating and resident vascular cells, such as fibro-
timal hyperplasia with Ad-AST. Grafts were transfected
idase (top left), antisense to transforming growth factor
ric vein is shown at the bottom right. Neointimal growth
h preservation of the adventitial/medial layer. Arrows
; A, adventitia/media. Each picture was taken at 100
2 wk 4 wk 12 wk
28,865 (265)* 46,062 (319)* 85,334 (861)*
53,307 (258) 95,050 (511)* 137,171 (266)
25,741 (181) 74,666 (253)* 401,158 (508)*
50,726 (180)* 84,351 (154)* 66,227 (283)
204,079 (1874) 223,350 (1101) 271,604 (1305)*
198,158 (992) 182,334 (913) 125,167 (431)*
225,259 (1531) 234,582 (1255) 179,636 (485)
199,404 (621) 223,884 (555) 162,498 (495)
number of cells found in the cell layer is given after the area measurement.)ed in
lactos
igast
t, wit
tima8)
9)
6)
7)
63)
3)
96)
16)blasts and ECs, can contribute mcp-1 during IH develop-
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and protein expression is cell dependent, with downregu-
lation of MCP-1 in EC and upregulation in fibroblasts (the
effect on vascular SMCs has not been studied).43,44 MCP-1
promotes leukocyte transmigration via a gradient-depen-
dent mechanism45; at sites of MCP-1 overexpression, there
is increased accumulation of monocytes. Recent work sup-
ports the theory that macrophages may be responsible for a
large part of the pathophysiology observed in vein
grafts.46,47 In our own work with macrophage-depleted
animals, we have observed dramatic diminution of IH in
our rat model of vein graft IH after depleting monocytes
and macrophages by using liposomal clodronate.28,48
In addition to MCP-1 expression leading to collagen
production via TGF-1, there is some support for TGF-1
expression leading to additional MCP-1 production,49,50
and this implies that these two cytokines have an amplifica-
tion effect in vivo. We did observe a reduction of mcp-1
mRNA with a reduction in TGF-1 in the body of the
graft. This reduction in mcp-1 mRNA did not result in a
consistent reduction in cells producing MCP-1 protein in
the graft perianastomotic cross sections. When the peri-
anastomotic region was examined for TGF-1 by IHC, the
reduction in TGF-1 as measured by IHCwas not nearly as
dramatic as the reduction in TGF-1 as measured by
Fig 6. Reduction in transforming growth factor 1 (T
messenger RNA (mRNA). Overall, the reduction inmcp
control groups, but this effect did not reach significance a
were both measured for each of the grafts, further analy
completely dependent on the reduction in tgf-1 (P 
polymerase chain reaction with normalization to mRNA
For each treatment/time point, n  5 vein grafts.ELISA, which measured average TGF-1 protein through-out the graft body. The ELISA data are normalized to
micrograms of DNA (ie, cells), whereas the IHC results are
normalized to cross-sectional area (ie, cells and ECM).
Because TGF-1 causes the production of ECM, increases
or decreases of TGF-1 may be partially masked in IHC
morphometry by corresponding increases and decreases in
ECM. It is also possible that the Ad-AST is less effective at
preventing TGF-1 expression by the perianastomotic re-
gion, which is injured by the trauma of suturing, in addition
to adapting to the arterial environment. A second possibil-
ity is that Ad-AST treatment only affects the vein wall cells
present at the time of grafting and not TGF-1 expression
by infiltrating monocytes/macrophages. As a result,
TGF-1 expression in the vein graft may be in part due to
the infiltrating monocytes and macrophages. In addition,
the infiltrating macrophages also release mcp-1 protein,
which may account for the observed reduction in MCP-1
mRNA without a consistent reduction of MCP-1 protein.
The reduction in tgf-1 mRNA by Ad-AST at the 4-
and 12-week time points exceeds what would be expected
given the observed duration of -galactosidase activity after
infection by Ad-GAL and given that antisense to tgf-1
could be detected in only 25% of the 4- and 12-week grafts.
Because TGF-1 promotes its own expression, by reducing
TGF-1 production at the early time points, the Ad-AST
1) reduces monocyte chemotactic protein 1 (MCP-1)
RNA in the Ad-AST group was significant vs each of the
me points individually. Because tgf-1 andmcp-1mRNA
s able to show that the reduction in mcp-1 mRNA was
1). Measurements were made by relative quantitative
ls of hypoxanthine phosphoribosyltransferase (HPRT).GF-
-1m
t all ti
sis wa
.000
levetreatment may have reduced the stimulus for TGF-1
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Volume 41, Number 3 Wolff et al 507protein production at the later time points and, therefore,
may have had an effect past the time when high levels of
antisense mRNA were produced.
It is interesting to note that the Ad-GAL control often
showed more TGF-1 mRNA, total protein, bioactive
protein, IH, andmcp-1 RNA than sham or Ad-CMVpLpA.
This effect could have been due to inflammation caused by
the expressed -galactosidase protein. In addition, virus
proteins can also invoke an immune response, and the
antisense treatment would have had to overcome this stim-
ulus to TGF-1 production to show a significant reduction
in TGF-1 protein vs sham. This may account for the
inconsistent results when neointimal growth and cellularity
were quantified. Whereas the reduction in neointimal area
was significant vs sham at 2 and 4 weeks, significance was
lost at 12 weeks. The 12-week time point was when Ad-
CMVpLpA (empty virus) showed a massive amount of IH.
The adenovirus that delivered the antisense to tgf-1 may
have stimulated additional IH over what is observed when
the graft is not treated with virus. The antisense treatment
then mitigated the development of IH, but not to a level
less than that seen in a vein graft that has not been treated
with virus. Future studies will investigate new methods of
delivery of antisense-expressing constructs, such as lipo-
somes or naked DNA, and will compare results from these
constructs with other methods of inhibiting
TGF-1.32,51,52
The long-term goal of our research is to identify a
clinically effective preoperative treatment that would pre-
vent vein graft stenosis and occlusion secondary to IH. This
study investigates altering TGF-1 expression and shows
reduced IH. Future experiments will attempt to target the
specific molecules, cell types, or processes (such as MCP-1,
ECM synthesis, chemotaxis, proliferation/apoptosis, fibro-
blast differentiation, and ECM remodeling) that may have
been altered by reducing TGF-1 expression. This targeted
approach may have the additional advantage of limiting IH
without blocking potentially positive effects of TGF-1 as
the vein remodels to accommodate the increased pressures
found in the arterial system.
Glen Leverson, PhD, of the Department of Surgery
Biostatistics Office, assisted in the statistical analysis. We
thank Dr Tausif Alam, University of Wisconsin, for the
generous gift of replication-defective adenovirus contain-
ing the gene encoding -galactosidase (Ad-GAL). Ad-
CMVpLpA() was provided by theUniversity ofMichigan
Medical Center Vector Core.
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